R. Jones

发表

Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles.

M. Pfaller, L. Putnam, W. Howard, 1997, Diagnostic microbiology and infectious disease.

Vitek GPS card susceptibility testing accuracy using direct inoculation from BACTEC 9240 blood culture bottles.

M. Pfaller, W. Howard, F. Koontz, 1996, Diagnostic microbiology and infectious disease.

Evaluation of the Etest Method for Determining Voriconazole Susceptibilities of 312 Clinical Isolates ofCandida Species by Using Three Different Agar Media

M. Pfaller, R. Jones, S. Messer, 2000, Journal of Clinical Microbiology.

Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of CandidaSpecies

A. Bolmström, M. Pfaller, R. Jones, 2001, Journal of Clinical Microbiology.

Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates ofCandida Species

A. Bolmström, M. Pfaller, R. Jones, 2001, Journal of Clinical Microbiology.

Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for Antifungal Susceptibility Testing of the New Triazoles Voriconazole, Posaconazole, and Ravuconazole

M. Pfaller, R. Jones, A. Espinel-Ingroff, 2004, Journal of Clinical Microbiology.

Antibiotic resistance. Epidemiology and therapeutics.

R N Jones, W Schaffner, W. Schaffner, 1992, Diagnostic microbiology and infectious disease.

Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.

M. Pfaller, R. Jones, 2001, Postgraduate medicine.

Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers

F. Tenover, M. Pfaller, R. Jones, 1994, Journal of clinical microbiology.

Oxacillin- and Quinolone-Resistant Staphylococcus Aureus in Sao Paulo, Brazil: A Multicenter Molecular Epidemiology Study

Ronald N. Jones, R. Jones, R. Hollis, 1993, Infection Control & Hospital Epidemiology.

Evaluation of interhospital spread of methicillin-resistant Staphylococcus aureus in Sao Paulo, Brazil, using pulsed-field gel electrophoresis of chromosomal DNA.

R. Jones, R. Hollis, H. Sader, 1994, Infection control and hospital epidemiology.

Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.

R N Jones, R. Wenzel, M. Nettleman, 1991, The American journal of medicine.

Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic

R. Jones, A. Barry, P. Fuchs, 1990, Journal of clinical microbiology.

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

D. Low, M. Pfaller, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Bacterial resistance: a worldwide problem.

Ronald N. Jones, M. Pfaller, R. Jones, 1998, Diagnostic microbiology and infectious disease.

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.

Jerome J. Schentag, R. Jones, D. M. Johnson, 1998, Diagnostic microbiology and infectious disease.

Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections.

R. Jones, W. Wilson, Ronald N. Jones, 1998, Diagnostic microbiology and infectious disease.

Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.

Ronald N. Jones, R. Wenzel, M. Edmond, 1997, Diagnostic microbiology and infectious disease.

Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.

M. Pfaller, R. Jones, 1997, Diagnostic microbiology and infectious disease.

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

Jerome J. Schentag, R. Jones, D. M. Johnson, 1997, Diagnostic microbiology and infectious disease.

In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.

M. Pfaller, R. Jones, S. Marshall, 1997, Diagnostic microbiology and infectious disease.

Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests.

J. Hindler, G. Doern, R. Jones, 1996, Diagnostic microbiology and infectious disease.

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.

R. Jones, M. S. Barrett, 1996, Diagnostic microbiology and infectious disease.

Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

Pfaller, D. Mathai, M. Pfaller, 2001, Diagnostic microbiology and infectious disease.

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!

M. Pfaller, R. Jones, M. Beach, 2001, Diagnostic microbiology and infectious disease.

Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

D. McClish, R. Wenzel, M. Edmond, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.

M. Pfaller, D. Diekema, R. Jones, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

R. Jones, S. Bhavnani, P. Ambrose, 2003, Antimicrobial Agents and Chemotherapy.

Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.

M. Pfaller, R. Jones, A. Ehrhardt, 2001, The American journal of medicine.

Prevalence of Extended-Spectrum β-Lactamase-Producing Enterobacter cloacae in the Asia-Pacific Region: Results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001

R. Jones, J. Bell, J. Turnidge, 2003, Antimicrobial Agents and Chemotherapy.

Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen

M. Cormican, R. Jones, S. Marshall, 1996, Journal of clinical microbiology.

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.

R. Jones, A. Gales, H. Sader, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.

M. Castanheira, P. Rhomberg, M. Pfaller, 2015, Diagnostic microbiology and infectious disease.

Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.

R. Jones, D. Hoban, F. Marco, 1994, Journal of chemotherapy.

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

Ronald N. Jones, R. Ramphal, J. Turnidge, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

E. Baron, R. Jones, 1995, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.

R. Jones, K. Aldridge, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.

Ronald N. Jones, M. Pfaller, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).

Ronald N. Jones, D. Mathai, M. Pfaller, 2001, Diagnostic microbiology and infectious disease.

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Ronald N. Jones, L. Saiman, J. Burns, 2001, Diagnostic microbiology and infectious disease.

In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.

R. Jones, K. Aldridge, A. Barry, 1992, Diagnostic microbiology and infectious disease.

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

M. Pfaller, R. Jones, S. Messer, 1998, Diagnostic microbiology and infectious disease.

Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

M. Pfaller, D. Diekema, R. Jones, 2003, Journal of Clinical Microbiology.

Key considerations in the treatment of complicated staphylococcal infections.

R. Jones, Ronald N. Jones, 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The lipochromes of sea anemones: Carotenoid pigments of Actinia equina, Anemonia sulcata, Actinoloba dianthus and Tealia felina.

R. Jones, I. Heilbron, H. Jackson, 1935, The Biochemical journal.

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution

M. Ghannoum, M. Castanheira, S. Lockhart, 2012, Journal of Clinical Microbiology.

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp

J. Turnidge, D. Diekema, R. Jones, 2009, Journal of Clinical Microbiology.

Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.

J. Turnidge, J. Verhoef, M. Pfaller, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Ronald N. Jones, R. Wenzel, M. Edmond, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).

R. Jones, T. Fritsche, H. Sader, 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone

R. Jones, S. Marshall, 1993, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins

R. Jones, R. R. Packer, 1982, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Journal of chemotherapy.

In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.

R. Jones, D. M. Johnson, C. M. Flynn, 1996, Journal of chemotherapy.

International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and Antifungal Susceptibilities of Isolates Collected in 1997 in the United States, Canada, and South America for the SENTRY Program

F. T. P. Group, M. Pfaller, G. Doern, 1998, Journal of Clinical Microbiology.

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.

Ronald N. Jones, R. Wenzel, M. Edmond, 1998, Diagnostic microbiology and infectious disease.

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

J. Verhoef, M. Pfaller, G. Doern, 1999, Diagnostic microbiology and infectious disease.

Changing patterns of resistance to new beta-lactam antibiotics. In vitro efficacy of cefoperazone against bacterial pathogens.

R. Jones, 1984, The American journal of medicine.

Dissemination and genetic context analysis of bla(VIM-6) among Pseudomonas aeruginosa isolates in Asian-Pacific Nations.

M. Castanheira, R. Jones, J. Bell, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Evaluation of the Discriminatory Powers of the Dienes Test and Ribotyping as Typing Methods for Proteus mirabilis

M. Pfaller, G. Doern, R. Jones, 2000, Journal of Clinical Microbiology.

Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases.

M. Pfaller, R. Jones, P. Winokur, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates

Ronald N. Jones, C. M. Flynn, R. Jones, 1997, Journal of Clinical Microbiology.

CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.

F. Koontz, R. Jones, M. S. Barrett, 1992, Diagnostic microbiology and infectious disease.

Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.

Ronald N. Jones, D. Guay, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.

M. Castanheira, R. Jones, A. Gales, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Ronald N. Jones, R. Jones, L. Deshpande, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.

F. Koontz, R. Jones, M. S. Barrett, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity of RU-66647, a new ketolide.

R. Jones, D. Biedenbach, 1997, Diagnostic microbiology and infectious disease.

In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004

R. Jones, D. Biedenbach, C. Jamjian, 1997, Antimicrobial agents and chemotherapy.

Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem?

R. Jones, M. L. Sánchez, K. K. Flint, 1993, Diagnostic microbiology and infectious disease.

In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin

R. Jones, A. Barry, C. Thornsberry, 1988, Antimicrobial Agents and Chemotherapy.

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

G. Doern, R. Jones, D. Hoban, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

R. Ramphal, M. Pfaller, R. Jones, 2000, Diagnostic microbiology and infectious disease.

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

Ronald N. Jones, R. Jones, S. Bhavnani, 2000, Diagnostic microbiology and infectious disease.

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

M. Cormican, R. Jones, 1997, Antimicrobial agents and chemotherapy.

Antimicrobial activity and interaction of pefloxacin and its principal metabolites

R. Jones, The Collaborative Antimicrobial Susceptibility Testing Group, 1989, European Journal of Clinical Microbiology and Infectious Diseases.

Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.

R. Jones, D. M. Johnson, 1996, Diagnostic microbiology and infectious disease.

Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Pfaller, R. Jones, 2001, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Comparative Antimicrobial Potency of Meropenem Tested Against Gram-Negative Bacilli: Report from the MYSTIC Surveillance Program in the United States (2004)

P. Rhomberg, R. Jones, T. Fritsche, 2005, Journal of chemotherapy.

In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood

M. Pfaller, D. Diekema, R. Jones, 2003, Journal of Clinical Microbiology.

M. Pfaller, D. Diekema, R. Jones, 2002, International journal of antimicrobial agents.

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).

R. Jones, A. Bolmstrôm, C. Ballow, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program

M. Pfaller, D. Diekema, R. Jones, 2001, Journal of Clinical Microbiology.

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Ronald N. Jones, D. Low, R. Jones, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

R. Ramphal, M. Pfaller, R. Jones, 2000, Diagnostic microbiology and infectious disease.

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.

Ronald N. Jones, R. Ramphal, M. Pfaller, 2000, International journal of antimicrobial agents.

Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).

Ronald N. Jones, R. Wenzel, M. Edmond, 1997, Diagnostic microbiology and infectious disease.

Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.

R. Wenzel, M. Edmond, M. Pfaller, 1997, Diagnostic microbiology and infectious disease.

Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.

M. Pfaller, R. Jones, S. Marshall, 1997, Diagnostic microbiology and infectious disease.

Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program.

R. Wenzel, M. Pfaller, R. Jones, 1997, Diagnostic microbiology and infectious disease.

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.

R. Jones, 1996, The American journal of medicine.

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

J. Verhoef, R. Jones, A. Gales, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Protocol for the study of drug interferences in laboratory tests: cefotaxime interference in 24 clinical tests.

R. Jones, J. Mullooly, W. Horner, 1983, Clinical chemistry.

Proposed disk diffusion susceptibility criteria for ofloxacin

R. Jones, A. Barry, P. Fuchs, 1985, Journal of clinical microbiology.

Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.

R. Jones, M. S. Barrett, W. Hoover, 1992, Diagnostic microbiology and infectious disease.

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.

R. Jones, J. Bell, J. Turnidge, 2002, International journal of antimicrobial agents.

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).

Ronald N. Jones, M. Pfaller, R. Jones, 2001, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens).

M. Cormican, R. Jones, 1995, Diagnostic microbiology and infectious disease.

Cefmetazole (CS-1170), a "new" cephamycin with a decade of clinical experience.

Ronald N. Jones, R. Jones, 1989, Diagnostic microbiology and infectious disease.

In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).

T. Barrett, M. Pfaller, G. Doern, 1998, Diagnostic microbiology and infectious disease.

MINIREVIEW Antimicrobial Susceptibility Testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae

Ronald N. Jones, G. Doern, R. Jones, 2022 .

Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests

R. Jones, A. Barry, 1988, Journal of clinical microbiology.

In vitro technical comment: Branhamella catarrhalis assessing beta-lactamase production

R. Jones, D. Amsterdam, 1986 .

Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program.

R. Jones, Ronald N. Jones, 2001, Archives of pathology & laboratory medicine.

Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program.

M. Pfaller, G. Doern, R. Jones, 1999, Archives of pathology & laboratory medicine.

Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.

R. Jones, M. L. Sánchez, 1994, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.

Ronald N. Jones, P. Rhomberg, M. Pfaller, 2000, American journal of obstetrics and gynecology.

Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Microbiological and Epidemiological Characterization of Imipenem-Resistant Pseudomonas aeruginosa Strains from a Brazilian Tertiary Hospital: Report from the SENTRY Antimicrobial Surveillance Program

R. Jones, H. Sader, R. Mendes, 2006, Journal of chemotherapy.

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.

R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates

R. Jones, A. Barry, P. Fuchs, 1984, Antimicrobial Agents and Chemotherapy.

Characterization of extended spectrum beta-lactamase-producing Klebsiella pneumoniae from Beijing, China.

R. Jones, P. Winokur, D. Shen, 2001, International journal of antimicrobial agents.

Evaluation of S1 chromogenic cephalosporin beta-lactamase disk assay tested against gram-positive anaerobes, coagulase-negative staphylococci, Prevotella spp. and Enterococcus spp.

R. Jones, S. Marshall, L. D. Sutton, 1995, Diagnostic microbiology and infectious disease.

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes

R. Jones, D. Biedenbach, 1995, Antimicrobial agents and chemotherapy.

Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.

R. Jones, H. Sader, M. Erwin, 1994, Diagnostic microbiology and infectious disease.

Review of the in vitro spectrum of activity of imipenem.

Ronald N. Jones, R. Jones, Ronald N. Jones, 1985, The American journal of medicine.

Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability.

L. Ayers, R. Jones, A. Barry, 1985, Diagnostic microbiology and infectious disease.

Antimicrobial activity of ten macrolide, linsosamine and streptogramin drugs tested againstLegionella species

R. Jones, D. M. Johnson, M. S. Barrett, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

M. Pfaller, R. Jones, M. Pfaller, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method.

R. Jones, A. Barry, 1987, The Journal of antimicrobial chemotherapy.

In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin

R. Jones, A. Barry, C. Thornsberry, 1987, Antimicrobial Agents and Chemotherapy.

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).

Ronald N. Jones, M. Pfaller, R. Jones, 2000, Diagnostic microbiology and infectious disease.

Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).

M. Pfaller, R. Jones, A. Gales, 2000, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998).

M. Pfaller, R. Jones, A. Gales, 2000, Diagnostic microbiology and infectious disease.

In Vitro Antibacterial Activity of Oral Cephalosporins

R. Jones, 1995 .

In-vitro studies of meropenem.

R. Jones, A. Barry, C. Thornsberry, 1989, The Journal of antimicrobial chemotherapy.

Conventional dogma applied to quinolones? Time for a change.

R. Jones, 2001, The Journal of antimicrobial chemotherapy.

Review of the in-vitro spectrum and characteristics of cefmetazole (CS-1170).

R. Jones, 1989, The Journal of antimicrobial chemotherapy.

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.

R. Jones, D. Biedenbach, M. S. Barrett, 1999, Diagnostic microbiology and infectious disease.

The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance.

R. Jones, 1996, Diagnostic microbiology and infectious disease.

Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.

R. Jones, G. Zurenko, 1993, Diagnostic microbiology and infectious disease.

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.

Ronald N. Jones, P. Murray, R. Jones, 1993, Diagnostic microbiology and infectious disease.

In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

M. Pfaller, D. Diekema, R. Jones, 2002, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

M. Brandt, M. Pfaller, G. Doern, 1998, Antimicrobial Agents and Chemotherapy.

Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).

M. Pfaller, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

F. Aarestrup, P. McDermott, L. Piddock, 2004, Microbial drug resistance.

Interpretive criteria for temocillin disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1985, European Journal of Clinical Microbiology.

Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.

R. Jones, 1992, The American journal of medicine.

In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci.

M. Pfaller, R. Jones, 1997, Diagnostic microbiology and infectious disease.

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.

R. Jones, D. Biedenbach, 1996, Diagnostic microbiology and infectious disease.

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

R. Jones, T. Fritsche, R. Jones, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species

M. Castanheira, M. Pfaller, D. Diekema, 2010, Journal of Clinical Microbiology.

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

M. Castanheira, S. Lockhart, M. Pfaller, 2012, Journal of Clinical Microbiology.

Single-dose cephalosporin prophylaxis of 929 surgical procedures in a prepaid group practice: a prospective, randomized comparison of cefoperazone and cefotaxime.

R. Jones, W. Wojeski, 1987, Diagnostic microbiology and infectious disease.

Antibiotic prophylaxis of 1,036 patients undergoing elective surgical procedures. A prospective, randomized comparative trial of cefazolin, cefoxitin, and cefotaxime in a prepaid medical practice.

R. Jones, M. Searles, W. Wojeski, 1987, American journal of surgery.

Cefotaxime is extensively used for surgical prophylaxis.

R. Jones, H. Sader, 1992, American journal of surgery.

Review of cefotaxime sodium for surgical prophylaxis. A model for the evolution toward single-dose or short-course cost-effective regimens.

R. Jones, 1990, Diagnostic microbiology and infectious disease.

Single-dose surgical prophylaxis using ticarcillin/clavulanic acid (Timentin): a prospective, randomized comparison with cefotaxime.

R. Jones, W. Wojeski, 1987, Diagnostic microbiology and infectious disease.

blaVIM-2 and blaVIM-7 Carbapenemase-Producing Pseudomonas aeruginosa Isolates Detected in a Tertiary Care Medical Center in the United States: Report from the MYSTIC Program

R. Jones, G. Bodey, K. Rolston, 2006, Journal of Clinical Microbiology.

Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study.

R. Jones, K. A. Gordon, D. Biedenbach, 2004, The Journal of antimicrobial chemotherapy.

Comparative evaluation of etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria.

R. Jones, S. Marshall, P. Rhomberg, 1997, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.

R. Jones, H. Sader, D. Biedenbach, 2001, Brazilian Journal of Infectious Diseases.

In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.

R. Jones, F. Sabatelli, R. Hare, 2001, The Journal of antimicrobial chemotherapy.

Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health.

R. Jones, S. Marshall, 1999, Diagnostic microbiology and infectious disease.

Automation of polymerase chain reaction tests to achieve acceptable contamination rates.

R. Jones, W. Wilke, L. D. Sutton, 1995, Clinical chemistry.

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.

R. Jones, M. Erwin, M. Erwin, 1995, Diagnostic microbiology and infectious disease.

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

R. Jones, M. Erwin, M. Erwin, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.

R. Jones, S. Marshall, M. Erwin, 1999, Diagnostic microbiology and infectious disease.

Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.

M. Brandt, M. Pfaller, G. Doern, 1999, Diagnostic microbiology and infectious disease.

New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.

R. Jones, M. Bale, M. Erwin, 1992, Diagnostic microbiology and infectious disease.

Molecular Epidemiology of Extended-Spectrum β-Lactamase-Producing, Fluoroquinolone-Resistant Isolates of Klebsiella pneumoniae in Taiwan

M. Pfaller, R. Jones, S. Messer, 2002, Journal of Clinical Microbiology.

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group.

M. Pfaller, R. Jones, A. Gales, 2000, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Practical approach to the identification of clinically relevant Enterococcus species.

Ronald N. Jones, D. Low, B. Willey, 1999, Diagnostic microbiology and infectious disease.

Evaluation of Vitek and API 20S for species identification of enterococci.

R. Jones, H. Sader, D. Biedenbach, 1995, Diagnostic microbiology and infectious disease.

Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.

R. Wenzel, R. Jones, J. Ena, 1993, Journal of chemotherapy.

Re-evaluation of the Role of Broad-Spectrum Cephalosporins Against Staphylococci by Applying Contemporary In-Vitro Results and Pharmacokinetic- Pharmacodynamic Principles

M. Pfaller, R. Jones, S. Bhavnani, 2007, Journal of chemotherapy.

Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil.

M. Pfaller, R. Jones, R. Hollis, 1993, Diagnostic microbiology and infectious disease.

The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.

R. Jones, A. Barry, R. R. Packer, 1989, Diagnostic microbiology and infectious disease.

Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline

P. Murray, R. Jones, J. Washington, 1989, Journal of clinical microbiology.

Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

M. Pfaller, R. Jones, S. Messer, 1998, Diagnostic microbiology and infectious disease.

Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates

R. Jones, D. M. Johnson, M. S. Barrett, 1992, Antimicrobial Agents and Chemotherapy.

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.

Ronald N. Jones, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

In Vitro Evaluation of BI 397, a Novel Glycopeptide Antimicrobial Agent

M. Pfaller, R. Jones, D. M. Johnson, 2001, Journal of chemotherapy.

Oxazolidinones: a review.

R. Jones, D. Diekema, 2000, Drugs.

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.

Ronald N. Jones, R. Jones, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.

Y. S. Chen, M. Pfaller, R. Jones, 1998, Diagnostic microbiology and infectious disease.

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

M. Pfaller, D. Diekema, R. Jones, 2004, Diagnostic microbiology and infectious disease.

In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates

M. Pfaller, D. Diekema, R. Jones, 2003, Antimicrobial Agents and Chemotherapy.

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.

M. Pfaller, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Diagnostic microbiology and infectious disease.

Clinical Isolates ofCandida spp. and Four Other Antifungal Agents against 394 In Vitro Activities of Voriconazole (UK-109,496)

M. Pfaller, R. Jones, S. Messer, 2013 .

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans

M. Pfaller, R. Jones, S. Messer, 2001, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp

M. Pfaller, R. Jones, S. Messer, 1998, Antimicrobial Agents and Chemotherapy.

Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99.

S. Richter, P. Rhomberg, M. Pfaller, 2001, Diagnostic microbiology and infectious disease.

Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.

Ronald N. Jones, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy.

M. Castanheira, G. Fadda, T. Spanu, 2009, Clinical Microbiology and Infection.

In Vitro Activity of β-Lactam Antimicrobial Agents in Combination with Aztreonam Tested Against Metallob-β-Lactamase-Producing Pseudomonas aeruginosa and Acinetobacter baumannii

R. Jones, H. Sader, P. Rhomberg, 2005, Journal of chemotherapy.

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.

M. Pfaller, R. Jones, 1997, Diagnostic microbiology and infectious disease.

Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.

M. Kinzig, G. Drusano, F. Sörgel, 2007, The Journal of antimicrobial chemotherapy.

Determining the value of antimicrobial surveillance programs.

R. Masterton, R. Jones, 2001, Diagnostic microbiology and infectious disease.

Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans

M. Pfaller, R. Jones, S. Messer, 2003, Journal of Clinical Microbiology.

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America).

M. Pfaller, G. Doern, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.

R. Jones, H. Sader, B. Runyon, 1995, Diagnostic microbiology and infectious disease.

In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis.

M. Cormican, R. Jones, B. Runyon, 1995, Journal of chemotherapy.

Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods

R. Jones, M. S. Barrett, P. Mehaffey, 1996, Journal of Clinical Microbiology.

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

M. Pfaller, R. Jones, M. Stilwell, 2001, Diagnostic microbiology and infectious disease.

In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates.

R. Wenzel, R. Jones, M. S. Barrett, 1992, Diagnostic microbiology and infectious disease.

Telavancin Activity Against Gram-Positive Bacteria Isolated from Patients with Skin and Skin-Structure Infections

M. Pfaller, R. Jones, H. Sader, 2010, Journal of chemotherapy.

In vitro activity of Ro 23-9424, ceftazidime, and eight other newer beta-lactams against 100 gram-positive blood culture isolates.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents

R. Jones, D. Biedenbach, 1997, Journal of clinical microbiology.

Activity of Mupirocin and 14 Additional Antibiotics against Staphylococci Isolated from Latin American Hospitals: Report from the SENTRY Antimicrobial Surveillance Program

R. Jones, S. S. Andrade, A. Gales, 2004, Journal of chemotherapy.

Activity of Ceftazidime-Avibactam and Comparator Agents Tested Against Isolates from Europe-Mediterranean Region Surveillance (2011)

R. Jones, H. Sader, R. Flamm, 2013 .

Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme.

M. Pfaller, R. Jones, P. Winokur, 2001, Diagnostic microbiology and infectious disease.

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.

R. Jones, M. Erwin, 2000, Diagnostic microbiology and infectious disease.

Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker.

B. Doebbeling, R. Wenzel, A. Widmer, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.

M. Pfaller, R. Jones, S. Messer, 1998, Medical mycology.

Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?

Ronald N. Jones, F. Baquero, R. Cantón, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

G. Eliopoulos, M. Pfaller, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.

M. Cormican, R. Jones, 1995, Journal of Antimicrobial Chemotherapy.

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

J J Schentag, R N Jones, Jerome J. Schentag, 1998, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.

R. Jones, D. Biedenbach, M. S. Barrett, 1998, Diagnostic microbiology and infectious disease.

In Vitro Antimicrobial Activity of Cinoxacin Against 2,968 Clinical Bacterial Isolates

R. Jones, P. Fuchs, 1976, Antimicrobial Agents and Chemotherapy.

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.

R. Jones, D. M. Johnson, M. Erwin, 1999, Diagnostic microbiology and infectious disease.

Resistance patterns among nosocomial pathogens: trends over the past few years.

Ronald N. Jones, R. Jones, 2001, Chest.

Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime

R. Jones, A. Barry, C. Thornsberry, 1989, Antimicrobial Agents and Chemotherapy.

A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy.

R. Jones, 1987, Diagnostic microbiology and infectious disease.

Interpretive standards and quality control guidelines for imipenem susceptibility tests with 10-micrograms disks

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs

R. Jones, H. Sader, H. Sader, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Stability of SM-7338, a new carbapenem in mediums recommended for the susceptibility testing of anaerobic bacteria and gonococci.

R. Jones, R. Gardiner, 1989, Diagnostic microbiology and infectious disease.

Multicenter in vitro evaluation of SM-7338, a new carbapenem

R. Jones, K. Aldridge, A. Barry, 1989, Antimicrobial Agents and Chemotherapy.

In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.

R. Jones, D. Hoban, R. Frei, 1993, Diagnostic microbiology and infectious disease.

In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.

R. Jones, A. Barry, C. Thornsberry, 1989, The Journal of antimicrobial chemotherapy.

In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101

R. Jones, K. Aldridge, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media.

R. Jones, S. Marshall, K. Kugler, 2000, International journal of antimicrobial agents.

Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods.

R. Jones, 1996, Diagnostic microbiology and infectious disease.

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.

R. Jones, M. S. Barrett, C. Jamjian, 1997, Diagnostic microbiology and infectious disease.

In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species.

R. Jones, M. S. Barrett, M. Barrett, 1996, Diagnostic microbiology and infectious disease.

Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections.

R. Jones, 1997, Diagnostic microbiology and infectious disease.

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.

M. Pfaller, G. Doern, R. Jones, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.

M. Pfaller, R. Jones, J. Washington, 1997, Diagnostic microbiology and infectious disease.

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.

M. Cormican, R. Jones, S. Marshall, 1996, Diagnostic microbiology and infectious disease.

Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test

P. Fernandes, J. Jorgensen, R. Jones, 1988, Journal of clinical microbiology.

Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.

R. Jones, A. Barry, 1987, The Pediatric infectious disease journal.

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative

R. Jones, M. S. Barrett, M. Erwin, 1997, Antimicrobial agents and chemotherapy.

In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

R. Jones, D. M. Johnson, M. Erwin, 1996, Antimicrobial agents and chemotherapy.

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations

R. Jones, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

R N Jones, R. Jones, H. Sader, 1995, Diagnostic microbiology and infectious disease.

In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli.

R. Wenzel, T. Perl, R. Jones, 1992, The Journal of antimicrobial chemotherapy.

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

R. Jones, B. B. Gooding, 1993, Antimicrobial Agents and Chemotherapy.

In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates.

M. Cormican, R. Jones, 1996, The Journal of antimicrobial chemotherapy.

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.

M. Pfaller, R. Jones, L. Deshpande, 2002, Diagnostic microbiology and infectious disease.

Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum

R. Jones, A. Barry, R. R. Packer, 1986, Antimicrobial Agents and Chemotherapy.

Antibacterial activity of fortimicin A compared with those of five other aminoglycosides, and factors affecting susceptibility tests

R. Jones, A. Barry, C. Baker, 1981, Antimicrobial Agents and Chemotherapy.

Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.

R. Jones, D. M. Johnson, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates

M. Cormican, R. Jones, S. P. Murphy, 1995, Irish journal of medical science.

Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).

M. Cormican, R. Jones, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.

R. Jones, D. Biedenbach, M. S. Barrett, 1994, Diagnostic microbiology and infectious disease.

In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.

P. Murray, R. Jones, J. Washington, 1993, Diagnostic microbiology and infectious disease.

Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests

R. Jones, A. Barry, 1989, Journal of clinical microbiology.

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

R. Jones, J. Washington, K. Aldridge, 1988, Diagnostic microbiology and infectious disease.

Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

R. Jones, A. Barry, 1983, Diagnostic microbiology and infectious disease.

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.

R. Jones, D. Biedenbach, M. S. Barrett, 1998, Diagnostic microbiology and infectious disease.

Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.

R. Jones, S. Marshall, L. Zerva, 1996, The Journal of antimicrobial chemotherapy.

In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

M. Pfaller, R. Jones, S. Messer, 2004, Mycopathologia.

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans

Ronald N. Jones, M. Klepser, M. Pfaller, 1997, Antimicrobial agents and chemotherapy.

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing

L. Ayers, R. Jones, A. Barry, 1982, Antimicrobial Agents and Chemotherapy.

In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.

P. Murray, R. Jones, J. Washington, 1993, Journal of chemotherapy.

Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit.

M. Burattini, R. Jones, R. Hollis, 1993, Diagnostic microbiology and infectious disease.

Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Determination of the ascorbic acid content of two medicinal plants in Nigeria.

L. Ayers, S. Brown, R. Jones, 2006 .

Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus.

R. Wenzel, A. Widmer, R. Jones, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of Clinical Microbiology.

Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories

R. Jones, A. Barry, C. Thornsberry, 1981, Journal of clinical microbiology.

Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.

R. Jones, M. Erwin, P. Hohl, 1993, Diagnostic microbiology and infectious disease.

In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

M. Pfaller, R. Jones, S. Messer, 2000, Antimicrobial Agents and Chemotherapy.

Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins

R. Jones, D. Sahm, C. Baker, 1983, Journal of clinical microbiology.

Disk diffusion and disk elution tests with A-56268 and erythromycin

R. Jones, A. Barry, C. Thornsberry, 1987, European Journal of Clinical Microbiology.

In vitro technical comment: Broth-disk elution method for anaerobic susceptibility testing; a simple unreliable test

R. Jones, D. Amsterdam, 1988 .

Evaluation of in vitro methods for testing ceftriaxone against anaerobic bacteria, including quality control guidelines

R. Jones, A. Barry, 1988, Journal of Clinical Microbiology.

Ceftizoxime and cefoxitin susceptibility testing against anaerobic bacteria: comparison of results from three NCCLS methods and quality control recommendations for the reference agar dilution procedure.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Cefoperazone and cefoperazone-sulbactam susceptibility tests with anaerobic bacteria by the thioglycolate disk elution method

R. Jones, A. Barry, R. R. Packer, 1985, Journal of Clinical Microbiology.

Collaborative evaluation of the micro-media systems anaerobe susceptibility panel: comparisons with reference methods and test reproducibility

R. Jones, A. Barry, J. Swenson, 1982, Journal of clinical microbiology.

Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis

R. Jones, D. Sahm, C. Baker, 1984, Journal of clinical microbiology.

Gram-positive superinfections following beta-lactam chemotherapy: The significance of the enterococcus

R. Jones, 2005, Infection.

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.

R. Jones, 1995, Diagnostic microbiology and infectious disease.

Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci

R. Jones, B. Buschelman, M. Bale, 1994, Journal of clinical microbiology.

Gram-positive superinfections: A consequence of modern β-lactam chemotheraphy

R. Jones, C. Thornsberry, 1985 .

Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.

R. Jones, A. Barry, P. Fuchs, 1982, Reviews of infectious diseases.

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose

M. Pfaller, R. Jones, A. Espinel-Ingroff, 1996, Journal of clinical microbiology.

In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.

M. Pfaller, G. Doern, R. Jones, 1998, Journal of Antimicrobial Chemotherapy.

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

M. Pfaller, S. Messer, R. Jones, 1997, Antimicrobial agents and chemotherapy.

Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965)

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Interlaboratory performance of disk agar diffusion and dilution antimicrobial susceptibility tests, 1979-1981. A summary of the microbiology portion of the College of American Pathologists (CAP) surveys.

R. Jones, D. Edson, 1982, American journal of clinical pathology.

Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study

L. Reller, R. Jones, A. Barry, 1981, Journal of clinical microbiology.

3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1984, European Journal of Clinical Microbiology.

Proposed zone standards for interpretation of fortimicin A disk diffusion tests

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: a collaborative study

R. Jones, A. Barry, T. Gavan, 1980, Antimicrobial Agents and Chemotherapy.

Evaluation of the Micro-Media System for Quantitative Antimicrobial Drug Susceptibility Testing: a Collaborative Study

R. Jones, A. Barry, T. Gavan, 1978, Antimicrobial Agents and Chemotherapy.

Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation.

R. Jones, A. Barry, C. Thornsberry, 1981, American journal of clinical pathology.

Netilmicin disk susceptibility tests: Effect of cations on the MIC correlates

R. Jones, A. Barry, C. Thornsberry, 1987, European Journal of Clinical Microbiology.

Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo

R. Jones, R. Ferraresi, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

In vitro evaluations of amikacin: an assessment of the currently used methods of disk diffusion and dilution susceptibility, antimicrobial synergy, and the measurement of amikacin concentrations.

R. Jones, 1986, The American journal of medicine.

Azlocillin, a ureido penicillin active against Pseudomonas aeruginosa: interpretive zone standards and quality control parameters for tests with 75-mu g disks

R. Jones, A. Barry, C. Thornsberry, 1982, Journal of clinical microbiology.

Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test

R. Jones, A. Barry, C. Thornsberry, 1981, Antimicrobial Agents and Chemotherapy.

Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.

R. Jones, D. M. Johnson, 1995, Diagnostic microbiology and infectious disease.

Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Susceptibility testing of Haemophilus influenzae--an international collaborative study in quality assessment.

R. Auckenthaler, I. Phillips, J. Williams, 1996, The Journal of antimicrobial chemotherapy.

In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

M. Pfaller, G. Doern, D. Diekema, 1999, Antimicrobial Agents and Chemotherapy.

Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000

M. Pfaller, R. Jones, S. Messer, 2002, Antimicrobial Agents and Chemotherapy.

Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.

M. Pfaller, R. Jones, S. Messer, 1998, Medical mycology.

In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits.

R. Jones, A. Barry, P. Fuchs, 1985, Diagnostic microbiology and infectious disease.

Evaluation of the MICUR system for quantitative antimicrobial susceptibility testing: a multiphasic comparison with reference methods

R. Jones, A. Barry, C. Thornsberry, 1982, Journal of clinical microbiology.

Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.

R. Jones, M. Erwin, A. M. Fix, 2001, Diagnostic microbiology and infectious disease.

False resistance to metronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality.

M. Cormican, R. Jones, M. Erwin, 1996, Diagnostic microbiology and infectious disease.

Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis.

L. Putnam, R. Jones, J. M. Jennings, 1994, Diagnostic microbiology and infectious disease.

The E-Test applied to susceptibility tests of gonococci, multiply-resistant enterococci, and Enterobacteriaceae producing potent beta-lactamases.

R. Jones, M. S. Barrett, M. L. Sánchez, 1992, Diagnostic microbiology and infectious disease.

An in vitro evaluation of HRE 664, a novel penem antibiotic.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Cefotetan: a review of the microbiologic properties and antimicrobial spectrum.

R. Jones, 1988, American journal of surgery.

Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.

P. Murray, F. Koontz, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains

R. Jones, C. Baker, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Antimicrobial Agents and Chemotherapy.

Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1988, Journal of clinical microbiology.

Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.

R. Jones, 1990, Diagnostic microbiology and infectious disease.

Stability of antimicrobials in Schaedler's anaerobic and brain heart infusion broths stored at --20 degrees C.

R. Jones, A. Barry, P. Fuchs, 1978, The Journal of antibiotics.

Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States

R. Jones, X. Y. Zhou, F. Goldstein, 1991, Antimicrobial Agents and Chemotherapy.

In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone

R. Jones, A. Barry, 1990, Antimicrobial Agents and Chemotherapy.

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Evaluation of the Sceptor microdilution antibiotic susceptibility testing system: a collaborative investigation

R. Jones, A. Barry, C. Thornsberry, 1981, Journal of clinical microbiology.

The antimicrobial activity of cefotaxime: Comparative multinational hospital isolate surveys covering 15 years

R. Jones, 1994, Infection.

Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.

R. Jones, K. Aldridge, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition.

R. Jones, A. Barry, P. Fuchs, 1982, The Journal of antimicrobial chemotherapy.

Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.

R. Jones, H. W. Wilson, 1983, Diagnostic microbiology and infectious disease.

Collaborative evaluation of the microbial profile system for quantitative antimicrobial susceptibility testing

R. Jones, A. Barry, E. Gerlach, 1983, Journal of clinical microbiology.

Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum

R. Jones, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

Evaluation of teicoplanin and vancomycin disk susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1986, Journal of clinical microbiology.

In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

R. Jones, A. Barry, 1989, The Journal of antimicrobial chemotherapy.

Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.

R. Jones, N. Yamane, Ronald N. Jones, 1991, Diagnostic microbiology and infectious disease.

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

R. Jones, A. Barry, A. Barry, 1989, Diagnostic microbiology and infectious disease.

The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.

R. Wenzel, R. Jones, J. Ena, 1993, JAMA.

The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens.

R N Jones, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1984, Journal of clinical microbiology.

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

R. Jones, A. Barry, P. Fuchs, 1981, The Journal of antimicrobial chemotherapy.

Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .

G. Drusano, L. Cosler, R. Jones, 2014, The Journal of antimicrobial chemotherapy.

Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)

R. Jones, A. Barry, 1988, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolates

L. Ayers, R. Jones, A. Barry, 1986, Antimicrobial Agents and Chemotherapy.

In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds

R. Jones, W. J. Novick, H. W. Wilson, 1982, Journal of clinical microbiology.

Evaluation of the sensititre microdilution antibiotic susceptibility system against recent clinical isolates: three-laboratory collaborative study

R. Jones, A. Barry, T. Gavan, 1980, Journal of clinical microbiology.

In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci

R. Jones, A. Barry, 1990, Antimicrobial Agents and Chemotherapy.

Use of Molecular and Reference Susceptibility Testing Methods in a Multicenter Evaluation of MicroScan Dried Overnight Gram-Positive MIC Panels for Detection of Vancomycin and High-Level Aminoglycoside Resistances in Enterococci

P. Murray, M. Pfaller, G. Doern, 1998, Journal of Clinical Microbiology.

Evaluation of a proprietary broth medium for microdilution susceptibility testing of nutritionally fastidious bacteria

R. Jones, A. Barry, J. Cotton, 1986, Journal of clinical microbiology.

Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

R. Jones, A. Barry, C. Thornsberry, 1982, Reviews of infectious diseases.

Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

R. Jones, C. Thornsberry, 1982, Reviews of infectious diseases.

Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.

R. Jones, A. Barry, C. Thornsberry, 1986, Diagnostic microbiology and infectious disease.

Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998

Ronald N. Jones, M. Pfaller, G. Doern, 2000, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Diagnostic microbiology and infectious disease.

The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.

R. Jones, A. Barry, R. R. Packer, 1984, Diagnostic microbiology and infectious disease.

Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.

R. Jones, A. Barry, 1983, Reviews of infectious diseases.

In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides.

R. Jones, A. Barry, C. Thornsberry, 1980, Cleveland Clinic quarterly.

In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides.

R. Jones, A. Barry, C. Thornsberry, 1980, The Journal of antimicrobial chemotherapy.

Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin

R. Jones, M. Erwin, 1992, Journal of clinical microbiology.

In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester.

R. Jones, D. M. Johnson, M. S. Barrett, 1991, Diagnostic microbiology and infectious disease.

Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates

R. Jones, M. Erwin, B. B. Gooding, 1992, Journal of clinical microbiology.

BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

R. Jones, A. Barry, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

R. Jones, A. Barry, P. Fuchs, 1985, Antimicrobial Agents and Chemotherapy.

Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Desacetylcefotaxime--another broad spectrum cephalosporin?

L. Ayers, R. Jones, A. Barry, 1989, The Journal of antimicrobial chemotherapy.

Activity of six contemporary antibacterial agents against 96 isolates from purulent meningitis: the contribution of desacetylcefotaxime to antimicrobial potency.

R. Jones, A. Barry, 1987, The Journal of antimicrobial chemotherapy.

The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs.

R. Jones, 1984, The Journal of antimicrobial chemotherapy.

Cefotaxime, cephalothin, and cephapirin: antimicrobial activity and synergy studies of cephalosporins with significant in vivo desacetyl metabolite concentrations.

R. Jones, R. R. Packer, 1984, Diagnostic microbiology and infectious disease.

Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium

R. Jones, A. Barry, 1983, Antimicrobial Agents and Chemotherapy.

Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935)

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Cefoperazone: evaluation of the in vitro activity and an analysis of the disk diffusion test.

R. Jones, A. Barry, C. Baker, 1980, Clinical therapeutics.

Cefoperazone: Spectrum of Antibacterial Activity and Disc Diffusion Testing

R. Jones, C. Thornsberry, 2012, Drugs.

Bacterial antibiotic resistance before and after clinical application in the United States.

R. Jones, A. Barry, 1987, Bulletin of the New York Academy of Medicine.

Temocillin: in vitro activity against 734 selected clinical isolates, including beta-lactamase-producing strains.

R. Jones, A. Barry, P. Fuchs, 1984, Diagnostic microbiology and infectious disease.

In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits

A L Barry, R N Jones, T L Gavan, 1983, Antimicrobial Agents and Chemotherapy.

Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone

R. Jones, A. Barry, C. Baker, 1982, Journal of clinical microbiology.

Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits

R. Jones, A. Barry, D. Gibbs, 1982, Journal of clinical microbiology.

BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

β-Lactam antibiotics: The first- and second-generation cephalosporins

R. Jones, D. Sahm, C. Thornsberry, 1985 .

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination

R. Jones, A. Barry, C. Thornsberry, 1987, Journal of clinical microbiology.

Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan.

Y. Chuang, R. Jones, L-T Wu, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000

M. Pfaller, D. Diekema, R. Jones, 2002, Journal of Clinical Microbiology.

Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001

R. Jones, K. Christiansen, J. Bell, 2004, Antimicrobial Agents and Chemotherapy.

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

R N Jones, R. Wenzel, M. Edmond, 1998, Diagnostic microbiology and infectious disease.

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

R N Jones, M. Pfaller, D. Diekema, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Critical appraisal of E test for the detection of fluoroquinolone resistance.

R. Jones, M. Erwin, J. L. Croco, 1996, The Journal of antimicrobial chemotherapy.

Minocycline therapy of aquarium granuloma. Case reports and literature review.

R. Jones, P. Contorer, 1979, Cutis.

Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.

P. Rhomberg, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination againstLegionella species

R. Jones, M. S. Barrett, M. Erwin, 1990, European Journal of Clinical Microbiology and Infectious Diseases.

Application of the Etest to antimicrobial susceptibility testing of Legionella spp.

P. Rhomberg, R. Jones, M. Bale, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.

R. Jones, M. S. Barrett, M. Erwin, 1991, Diagnostic microbiology and infectious disease.

Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp.

R. Jones, 1991, The Journal of antimicrobial chemotherapy.

Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.

F. Fernández-Cuenca, L. Martínez-Martínez, Á. Pascual, 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.

R. Jones, D. Biedenbach, M. Rospide, 2001, International Journal of Antimicrobial Agents.

Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians?

R. Jones, 1992, Diagnostic microbiology and infectious disease.

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.

R. Jones, M. Erwin, S. P. Murphy, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.

R. Jones, S. Marshall, 1994, Diagnostic microbiology and infectious disease.

In-vitro activity of FK-037, a new parenteral cephalosporin.

R. Jones, M. S. Barrett, M. Erwin, 1994, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample.

R. Jones, M. L. Sánchez, 1993, The Journal of antimicrobial chemotherapy.

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

P. Murray, R. Jones, J. Washington, 1993, Antimicrobial Agents and Chemotherapy.

Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

Comparison of the Vitek Gram-Positive Susceptibility 106 Card, the MRSA-Screen Latex Agglutination Test, and mecA Analysis for Detecting Oxacillin Resistance in a Geographically Diverse Collection of Clinical Isolates of Coagulase-Negative Staphylococci

M. Pfaller, D. Diekema, R. Jones, 2001, Journal of Clinical Microbiology.

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.

M. Pfaller, G. Doern, D. Diekema, 2000, International journal of antimicrobial agents.

Ofloxacin otic solution for treatment of otitis externa in children and adults.

R. Jones, M. Seidlin, J. Milazzo, 1997, Archives of otolaryngology--head & neck surgery.

Eight-year (2002-2009) Summary of the Linezolid (Zyvox® Annual Appraisal of potency and Spectrum; ZAAPS) Program in European Countries

D. Farrell, R. Jones, R. Mendes, 2011, Journal of chemotherapy.

Comparative In Vitro Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia Species Isolates Including Evaluation of Disk Diffusion and E Test Methods

T. Barrett, R. Jones, D. Biedenbach, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

In Vitro Evaluation of Ertapenem (MK-0826), a Long-Acting Carbapenem, Tested Against Selected Resistant Strains

R. Jones, 2001, Journal of chemotherapy.

Sustained Antimicrobial Activity of Tigecycline Against Methicillin-Resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 Through 2008

D. Farrell, R. Jones, H. Sader, 2010, Journal of chemotherapy.

Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria.

R. Jones, M. S. Barrett, P. Mehaffey, 1995, Diagnostic microbiology and infectious disease.

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

R. Jones, A. Gales, H. Sader, 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

NCCLS guidelines: revised performance standards for antimicrobial disk susceptibility tests

R. Jones, 1984 .

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.

W. Howard, R. Jones, D. Biedenbach, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.

R. Jones, D. Hoban, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol

R. Jones, B. Goldstein, T. Fritsche, 2005, Journal of chemotherapy.

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

Ronald N. Jones, R N Jones, W W Wilke, 2000, The Journal of antimicrobial chemotherapy.

Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997.

M. Pfaller, G. Doern, D. Diekema, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.

M. Pfaller, R. Jones, D. Biedenbach, 2001, International journal of antimicrobial agents.

Antimicrobial activity of CS-940, a new trifluorinated quinolone

R. Jones, D. Biedenbach, L. D. Sutton, 1995, Antimicrobial agents and chemotherapy.

Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.

L. Reller, R. Jones, M. L. Sánchez, 1992, Diagnostic microbiology and infectious disease.

Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis.

M. Pfaller, R. Jones, H. Sader, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Macrolide and Fluoroquinolone (Levofloxacin) Resistances amongStreptococcus pneumoniae Strains: Significant Trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997–1999)

M. Pfaller, R. Jones, 2000, Journal of Clinical Microbiology.

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.

M. Pfaller, G. Doern, R. Jones, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

R. Jones, A. Gales, Ronald N. Jones, 2000, Diagnostic microbiology and infectious disease.

Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.

R. Jones, 1999, Diagnostic microbiology and infectious disease.

Standardization of Broth Microdilution and Disk Diffusion Susceptibility Tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: Quality Control Standards for Ceftiofur, Enrofloxacin, Florfenicol, Gentamicin, Penicillin, Tetracycline, Tilmicosin, and Trimethoprim-Sulfamethoxazole

P. McDermott, G. Stein, R. Jones, 2001, Journal of Clinical Microbiology.

Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin

G. Doern, R. Jones, T. Haugen, 1996, Journal of clinical microbiology.

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria.

R. Jones, A. Gales, L. Deshpande, 2001, International journal of antimicrobial agents.

In vitro evaluation of A-56619 and A-56620, two new quinolones

A L Barry, R N Jones, C Thornsberry, 1986, Antimicrobial Agents and Chemotherapy.

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.

M. Pfaller, R. Jones, D. M. Johnson, 1999, Diagnostic microbiology and infectious disease.

Metallo-β-Lactamase Gene blaIMP-15 in a Class 1 Integron, In95, from Pseudomonas aeruginosa Clinical Isolates from a Hospital in Mexico

R. Jones, H. Sader, J. Silva-Sánchez, 2008, Antimicrobial Agents and Chemotherapy.

ANTIMICROBIAL ACTIVITY OF A NOVEL POLYMYXIN ANALOG (CB-182,804) TESTED AGAINST CLINICAL STRAINS OF GRAM-NEGATIVE BACILLI, INCLUDING COLISTIN-RESISTANT ORGANISMS

R. Jones, H. Sader, P. Rhomberg, 2010 .

Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.

M. Cormican, R. Jones, 1995, The Journal of antimicrobial chemotherapy.

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

R. Jones, K. Aldridge, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.

R. Jones, K. Aldridge, P. Fuchs, 1991, Diagnostic microbiology and infectious disease.

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.

R. Jones, 1995, Journal of chemotherapy.

Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin

R. Jones, A. Barry, C. Baker, 1980, Antimicrobial Agents and Chemotherapy.

MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin

P. Murray, F. Koontz, R. Jones, 1992, Journal of clinical microbiology.

Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group

R. Jones, A. Barry, 1990, Journal of clinical microbiology.

Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin

R. Jones, A. Barry, A. L. Barry, 1988, Antimicrobial Agents and Chemotherapy.

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

R. Jones, A. Barry, C. Baker, 1980, Antimicrobial Agents and Chemotherapy.

Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1979, Antimicrobial Agents and Chemotherapy.

Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.

M. Pfaller, R. Jones, D. M. Johnson, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.

R. Jones, F. Marco, M. S. Barrett, 1997, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil.

R. Jones, A. Gales, H. Sader, 2001, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection.

M. Klepser, R. Jones, R. Lewis, 2000, Diagnostic microbiology and infectious disease.

Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test

R. Jones, A. Barry, 1987, European Journal of Clinical Microbiology.

In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs

R. Jones, A. Barry, C. Thornsberry, 1983, Antimicrobial Agents and Chemotherapy.

Arbekacin Tested against Well Characterized Multidrug-Resistant (MDR) Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus (MRSA)

D. Farrell, R. Jones, H. Sader, 2014 .

Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1977, The American journal of the medical sciences.

Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds

R. Jones, M. Erwin, M. Barrett, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin

R. Jones, A. Barry, C. Thornsberry, 1984, Antimicrobial Agents and Chemotherapy.

The Epidemiology of Bacterial Resistance to Quinolones

R. Jones, T. O'Brien, F. Goldstein, 2012, Drugs.

Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides

R. Jones, A. Barry, 1987, European Journal of Clinical Microbiology.

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.

J. Hindler, G. Doern, R. Jones, 1994, Diagnostic microbiology and infectious disease.

Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition.

R. Jones, A. Barry, C. Thornsberry, 1982, The Journal of antimicrobial chemotherapy.

Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

R. Jones, A. Barry, P. Fuchs, 1979, American journal of clinical pathology.

Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis.

R. Jones, A. Barry, P. Fuchs, 1979, The Journal of antibiotics.

In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin

R. Jones, M. Erwin, 1992, Antimicrobial Agents and Chemotherapy.

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories

L. Ayers, R. Jones, A. Barry, 1984, Journal of clinical microbiology.

In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.

R. Jones, D. M. Johnson, M. Erwin, 1991, Diagnostic microbiology and infectious disease.

Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).

R. Jones, D. Biedenbach, 2000, Diagnostic microbiology and infectious disease.

Hospital Specificity, Region Specificity, and Fluconazole Resistance of Candida albicans Bloodstream Isolates

D. Soll, R. Wenzel, M. Edmond, 1998, Journal of Clinical Microbiology.

Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.

R. Jones, A. Barry, C. Thornsberry, 1985, Reviews of infectious diseases.

Antimicrobial activity of LY163892, an orally administered 1-carbacephem.

R. Jones, A. Barry, 1988, The Journal of antimicrobial chemotherapy.

Familial haemophagocytic reticulosis in first cousins.

R. Jones, N. Buist, T. R. Cavens, 1971, Archives of disease in childhood.

A specific urinary cast in acute pyelonephritis.

R. Jones, M. H. Haber, L. Lindner, 1980, American journal of clinical pathology.

Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

R. Jones, A. Barry, P. Fuchs, 1980, Clinical therapeutics.

Cefuroxime, an in vitro Comparison with Six Other Cephalosporins

R. Jones, A. Barry, P. Fuchs, 1977, Proceedings of the Royal Society of Medicine.

Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.

R. Jones, M. Erwin, 1992, Diagnostic microbiology and infectious disease.

Comment on: Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.

M. Toleman, R. Jones, T. Walsh, 2007, The Journal of antimicrobial chemotherapy.

Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.

R. Jones, W. J. Novick, M. Erwin, 1990, Diagnostic microbiology and infectious disease.

Antimicrobial activity of HR810 against 419 strict anaerobic bacteria

R. Jones, E. Gerlach, 1985, Antimicrobial Agents and Chemotherapy.

Cefotaxime in the treatment of prophylaxis of surgical infections.

D. Wittmann, R. Jones, G. Privitera, 1997, Journal of chemotherapy.

Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe.

M. Pfaller, R. Jones, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Detection of staphylococcal resistance to penicillinase-resistant penicillins. A comparison of two widely used disk diffusion methods.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria

A L Barry, R N Jones, T L Gavan, 1987, Journal of clinical microbiology.

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).

M. Pfaller, R. Jones, R. Mendes, 2017, Diagnostic microbiology and infectious disease.

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1

G. Doern, R. Jones, J. Washington, 1995, Journal of clinical microbiology.

Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity

R. Jones, 1989, Antimicrobial Agents and Chemotherapy.

In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic

R. Wenzel, R. Jones, M. L. Sánchez, 1992, Antimicrobial Agents and Chemotherapy.

Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination

Ronald N. Jones, R. Jones, A. Barry, 1988, Journal of clinical microbiology.

Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

R. Jones, A. Barry, R. R. Packer, 1986, Journal of Antimicrobial Chemotherapy.

The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.

R. Jones, A. Barry, C. Thornsberry, 1985, American Journal of Clinical Pathology.

Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

R. Jones, P. Fuchs, Peter C. Fuchs, 1989, The Journal of antimicrobial chemotherapy.

Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group.

R. Jones, D. Hoban, 1995, Chemotherapy.

Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.

R N Jones, M. Pfaller, G. Doern, 1998, Diagnostic microbiology and infectious disease.

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Ronald N. Jones, M. Pfaller, R. Jones, 1994, Diagnostic microbiology and infectious disease.

Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.

R. Jones, D. Hoban, F. Marco, 1994, Diagnostic microbiology and infectious disease.

In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent

R. Jones, A. Barry, W. J. Novick, 1982, Journal of clinical microbiology.

Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.

M. Cormican, R. Jones, 1995, Diagnostic microbiology and infectious disease.

R. Jones, L. D. Sutton, 1995, Journal of clinical microbiology.

Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Cefixime Disk Susceptibility Test Criteria

R. Jones, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

In vitro activity and disk susceptibility of Timentin: current status.

R. Jones, A. Barry, P. Fuchs, 1985, The American journal of medicine.

Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Evaluation of the cefonicid disk test criteria, including disk quality control guidelines

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Ceftibuten (7432-S, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines

R. Jones, A. Barry, The Collaborative Antimicrobial Susceptibility Testing Group, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro antimicrobial activity of tigemonam, a new orally administered monobactam

R. Jones, A. Barry, P. Fuchs, 1988, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.

L. Ayers, R. Jones, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter study.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Effect of beta-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic beta-lactamase producing bacteria.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae.

M. Cormican, R. Jones, M. Erwin, 1995, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.

P. Murray, R. Jones, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Kraft pulping and bleaching studies on young exotic hardwood species.

R. Jones, B. Fergus, B. Hannah, 1977 .

The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.

R. Jones, L. Harrell, D. Hoban, 1993, Diagnostic microbiology and infectious disease.

In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition.

R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins

R. Jones, H. W. Wilson, 1982, Infection.

Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin

R. Jones, A. Barry, C. Thornsberry, 1981, Antimicrobial Agents and Chemotherapy.

Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin.

G. Gray, R. Jones, D. Biedenbach, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Unpredictable interactions between cefotetan and penicillins or aminoglycosides.

R. Jones, A. Barry, R. R. Packer, 1984, Diagnostic microbiology and infectious disease.

Accuracy of broth microdilution and E test methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999).

M. Pfaller, R. Jones, L. Deshpande, 2001, Diagnostic microbiology and infectious disease.

Resistance to beta-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-98.

R. Jones, A. Fluit, L. Tzouvelekis, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

CONCISE COMMUNICATION Resistance to b-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997–98

R. Jones, A. Fluit, N. Legakis, 2003 .

DEFINITION AND ELIMINATION OF CERTAIN ERRORS IN THE HYDROLYSIS, EXTRACTION, AND SPECTROCHEMICAL ASSAY OF α- AND β- NEUTRAL URINARY 17-KETOSTEROIDS

R. Jones, N. Talbot, A. Butler, 1940 .

Interpretative criteria for the agar diffusion susceptibility test with azithromycin.

R. Jones, A. Barry, 1988, The Journal of antimicrobial chemotherapy.

Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus.

R. Wenzel, A. Widmer, R. Jones, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection.

M. Pfaller, R. Jones, R. Sesso, 1991, Journal of chemotherapy.

Ampicillin-resistant Haemophilus paraphrophilus laryngo-epiglottitis

R. Jones, J. Slepack, J. Bigelow, 1976, Journal of clinical microbiology.

Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks

R. Jones, L. Zerva, D. Biedenbach, 1996, Journal of clinical microbiology.

Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.

M. Pfaller, F. Koontz, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Antimicrobial activity of Ro 41-1879, a new catechol cephalosporin.

R. Jones, 1991, Journal of chemotherapy.

Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration

R. Jones, D. Biedenbach, 1996, Journal of clinical microbiology.

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Perspectives on the development of new antimicrobial agents for resistant gram-positive pathogens.

R. Jones, 2000, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.

R. Jones, M. Dudley, 1997, Diagnostic microbiology and infectious disease.

Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.

R. Jones, A. Barry, C. Baker, 1979, The Journal of antibiotics.

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.

M. Pfaller, R. Jones, A. Gales, 2000, Diagnostic microbiology and infectious disease.

Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.

R. Jones, M. Beach, L. Deshpande, 2000, The Journal of antimicrobial chemotherapy.

Proposed cefepime interpretive criteria for in-vitro susceptibility tests with Neisseria gonorrhoeae.

R. Jones, 1992, The Journal of antimicrobial chemotherapy.

Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Disk diffusion antimicrobial susceptibility testing of Neisseria gonorrhoeae.

R. Jones, 1990, MMWR. Morbidity and mortality weekly report.

Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.

P. Murray, R. Jones, J. Washington, 1990, Diagnostic microbiology and infectious disease.

Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species.

R. Jones, A. Houston, 1994, Journal of chemotherapy.

The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam.

R. Jones, A. Barry, P. Fuchs, 1986, American journal of clinical pathology.

E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates

R. Jones, D. Biedenbach, J. Hughes, 1993, Journal of clinical microbiology.

Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.

M. Pfaller, R. Jones, M. Jacobs, 2001, Diagnostic microbiology and infectious disease.

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.

M. Pfaller, R. Jones, D. M. Johnson, 2000, Diagnostic microbiology and infectious disease.

Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.

R. Jones, M. Erwin, M. Barrett, 1993, Diagnostic microbiology and infectious disease.

Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.

R. Jones, M. Barrett, 1992, Diagnostic microbiology and infectious disease.

MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin

P. Murray, F. Koontz, R. Jones, 1992, Journal of clinical microbiology.

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.

P. Murray, M. Pfaller, F. Koontz, 1991, Diagnostic microbiology and infectious disease.

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.

R. Jones, T. Fritsche, G. Moet, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Should novobiocin be clinically re-evaluated?

R. Jones, 1989, Diagnostic microbiology and infectious disease.

Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

R. Jones, A. Mutnick, M. Beach, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.

R. Jones, D. M. Johnson, D. Biedenbach, 2000, Diagnostic microbiology and infectious disease.

In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

R. Jones, D. Biedenbach, M. A. Croco, 1998, Diagnostic microbiology and infectious disease.

Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001).

R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin.

M. Pfaller, R. Jones, D. Walter, 2001, Diagnostic microbiology and infectious disease.

The ability of participant laboratories to detect penicillin-resistant Pneumococci. A report from the microbiology portion of the College of American Pathologists (CAP) surveys.

R. Jones, D. Edson, 1982, American Journal of Clinical Pathology.

J. Verhoef, M. Pfaller, G. Doern, 2000, Microbial drug resistance.

Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam.

R N Jones, R. Jones, D J Biedenbach, 1995, Diagnostic microbiology and infectious disease.

Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.

R. Jones, D. Biedenbach, T. Anderegg, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used

R. Jones, H. Sader, T. Anderegg, 2004, Journal of Clinical Microbiology.

Dalbavancin Activity Tested Against a Contemporary Collection of Gram-positive Bacteria from Hospitals in the UK and Ireland: Results from DECIDE Program

K. Bowker, M. Cormican, R. Howe, 2008 .

Dalbavancin and Selected Comparison Agents Tested Against Indicated Gram-positive Isolates in Italy: Results from the DECIDE Program

G. Fadda, R. Jones, G. Nicoletti, 2008 .

Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

G L Drusano, R Leary, V H Tam, 2007, The Journal of infectious diseases.

Stomatococcus mucilaginosus bacteremias. Typical case presentations, simplified diagnostic criteria, and a literature review.

F. Koontz, R. Jones, L. Holcomb, 1990, Diagnostic microbiology and infectious disease.

Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from U.S. Medical Centers in 2012

D. Farrell, R. Jones, R. Mendes, 2015, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.

T. Deguchi, R. Jones, M. Barrett, 1997, Diagnostic microbiology and infectious disease.

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.

R. Jones, D. Biedenbach, L. Deshpande, 2001, International Journal of Antimicrobial Agents.

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains.

R. Jones, D. Biedenbach, M. Beach, 1998, Diagnostic microbiology and infectious disease.

Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.

R. Jones, 1994, Diagnostic microbiology and infectious disease.

Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.

R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones.

R. Jones, D. M. Johnson, M. Erwin, 1993, Diagnostic microbiology and infectious disease.

In vitro activity of CP-74667 compared with four other fluoroquinolones.

R. Jones, M. Erwin, 1992, Diagnostic microbiology and infectious disease.

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.

Ronald N. Jones, M. Pfaller, G. Doern, 1998, Diagnostic microbiology and infectious disease.

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

P. Murray, M. Pfaller, F. Koontz, 1991, Journal of clinical microbiology.

Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium

R. Jones, M. Erwin, 1992, Journal of clinical microbiology.

Interpretive Criteria andQuality Control Guidelines forNeisseria gonorrhoeae Susceptibility TestStandardization forCefotetan

P. Murray, M. Pfaller, F. Koontz, 1991 .

In vitro antimicrobial activity of piperacillin and seven other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase producing strains.

R. Jones, C. Baker, C. Thornsberry, 1979, The Journal of antimicrobial chemotherapy.

Characterization of Antimicrobial Susceptibility Patterns Among Community-Acquired Isolates of ß-Haemolytic Streptococci in Latin America: Results of SENTRY Antimicrobial Surveillance Program.

M. Castanheira, R. Jones, 2003 .

Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.

R. Jones, A. Houston, 1994, Diagnostic microbiology and infectious disease.

In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamase producing strains.

M. Pfaller, R. Jones, L. Deshpande, 2000, International journal of antimicrobial agents.

Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents.

M. Cormican, R. Jones, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study

S. Rosenkranz, R. Jones, L. McNutt, 2017, BMC Infectious Diseases.

Antimicrobial Activity of Ceftaroline Tested Against Contemporary (2008) Bacteria Isolated From Community-Acquired Respiratory Tract Infections, Including Oxacillin- (Methicillin-) Resistant Staphylococcus aureus

R. Jones, T. Fritsche, H. Sader, 2008 .

Tentative disk diffusion susceptibility interpretive criteria for pefloxacin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.

M. Pfaller, R. Jones, S. Marshall, 1998, Diagnostic microbiology and infectious disease.

Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests.

Ronald N. Jones, M. Cormican, M. Pfaller, 1996, Diagnostic microbiology and infectious disease.

In vitro activity of ciprofloxacin against gram-positive cocci.

R. Jones, A. Barry, 1987, The American journal of medicine.

Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.

R. Jones, S. Marshall, M. Erwin, 1999, Diagnostic microbiology and infectious disease.

Standards and advisory activitiesNCCLS standards: Approved methods for dilution antimicrobial susceptibility tests

R. Jones, 1986 .

Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.

R. Jones, A. Wanger, D. Biedenbach, 1996, The Journal of antimicrobial chemotherapy.

A three category system for interpretation of disk tests for Pseudomonas-active penicillins and beta-lactamase hydrolysis/inhibition studies.

R. Jones, A. Barry, 1982, Journal of Antimicrobial Chemotherapy.

In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.

R. Jones, D. Biedenbach, M. Lewis, 1999, Diagnostic microbiology and infectious disease.

Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions.

R. Jones, H. Goodpasture, J. Peterie, 1988, Diagnostic microbiology and infectious disease.

β-lactam antibiotics: The extended spectrum penicillins

R. Jones, D. Sahm, C. Thornsberry, 1985 .

In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Piperacillin susceptibility tests by the single-disk agar diffusion technique

R. Jones, A. Barry, C. Baker, 1979, Antimicrobial Agents and Chemotherapy.

Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246.

M. Pfaller, F. Koontz, R. Jones, 1991, Journal of Antimicrobial Chemotherapy.

In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.

R. Jones, D. M. Johnson, D. Biedenbach, 1999, Diagnostic microbiology and infectious disease.

Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests withHaemophilus influenzae

R. Jones, M. Barrett, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group

R. Jones, M. Bale, 1993, Journal of clinical microbiology.

In vitro susceptibility test practices with Haemophilus influenzae among College of American Pathologists survey participants in the United States.

G. Doern, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.

R. Jones, D. M. Johnson, M. Erwin, 1991, Diagnostic microbiology and infectious disease.

Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases.

H. Goossens, R. Masterton, S. Unal, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Quality Control Guidelines for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole Disk Diffusion Susceptibility Tests with Nonsupplemented Mueller-Hinton Agar (CLSI M51-A Document) for Nondermatophyte Filamentous Fungi

M. Ghannoum, J. Turnidge, W. Schell, 2011, Journal of Clinical Microbiology.

Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA.

R. Jones, R. Frei, R. Hollis, 1994, The Journal of antimicrobial chemotherapy.

In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.

R. Jones, D. M. Johnson, D. Biedenbach, 1999, Diagnostic microbiology and infectious disease.

Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts?

D. Low, G. Doern, R. Jones, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro interaction between the penem FCE 22101 and ceftazidime

R. Jones, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones

R. Jones, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218

R. Jones, D. M. Johnson, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro evaluation of U63196-E (AC-1370): antimicrobial activity, beta-lactamase stability, and beta-lactamase inhibition.

R. Jones, 1984, Diagnostic microbiology and infectious disease.

Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species.

M. Cormican, R. Jones, D. M. Johnson, 1996, Diagnostic microbiology and infectious disease.

Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.

R. Jones, L. Deshpande, T. Anderegg, 2002, Diagnostic microbiology and infectious disease.

Combinations of orally administered beta-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae.

R. Jones, D. M. Johnson, 1998, Diagnostic microbiology and infectious disease.

In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.

R. Jones, D. Hoban, F. Marco, 1994, The Journal of antimicrobial chemotherapy.

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.

P. Murray, M. Pfaller, F. Koontz, 1992, Diagnostic microbiology and infectious disease.

Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program.

R. Jones, M. Wilson, G. Denys, 2000, Diagnostic microbiology and infectious disease.

Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae.

M. Cormican, R. Jones, A. Wanger, 1996, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility testing trends and accuracy in the United States. A review of the College of American Pathologists Microbiology Surveys, 1972-1989. Microbiology Resource Committee of the College of American Pathologists.

R N Jones, R. Jones, D. Edson, 1991, Archives of pathology & laboratory medicine.

Antimicrobial Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia spp.

R. Jones, D. M. Johnson, S. Marshall, 1999, Drugs.

Antimicrobial Activity of Gatifloxacin Against Campylobacter jejuni and Anaerobic Bacteria

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Antimicrobial Activity of Gatifloxacin Tested Against 1676 Gram-Positive Cocci Resistant to Ciprofloxacin

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Dilution and Disk Diffusion Methods

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Antimicrobial Spectrum of Gatifloxacin in the SENTRY Program

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

In Vitro Antimicrobial Activity of Gatifloxacin Against N. gonorrhoeae and H. influenzae

M. Pfaller, G. Doern, R. Jones, 1999, Drugs.

Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).

J. Verhoef, R. Jones, A. Fluit, 1999, Diagnostic microbiology and infectious disease.

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.

R. Jones, M. Erwin, C. L. Hayward, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.

M. Pfaller, G. Doern, R. Jones, 1998, Diagnostic microbiology and infectious disease.

Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species.

T. Perl, M. Pfaller, F. Koontz, 1994, Diagnostic microbiology and infectious disease.

Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System.

R N Jones, R. Jones, S. Marshall, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

R. Jones, L. Deshpande, 2000, Diagnostic microbiology and infectious disease.

In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application.

R. Jones, M. Bale, D. Hoban, 1993, Diagnostic microbiology and infectious disease.

Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms.

R. Jones, D. Biedenbach, K. Kugler, 1999, Diagnostic microbiology and infectious disease.

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.

D. Diekema, R. Jones, K. Rolston, 1999, Diagnostic microbiology and infectious disease.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone

M. Pfaller, R. Jones, D. Shortridge, 2018, Journal of Clinical Microbiology.

Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

M. Pfaller, R. Jones, D. M. Johnson, 1998, Journal of Antimicrobial Chemotherapy.

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates

J. Flynn, M. Cormican, R. Jones, 1998, Irish journal of medical science.

P574 Emergence and dissemination of metallo-β-lactamases producing strains in Europe: report from the SENTRY Antimicrobial Surveillance Program

R. Jones, T. Fritsche, H. Sader, 2007 .

Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against gram-positive isolates from Germany and the United States.

R. Jones, S. Marshall, H. Grimm, 1997, Diagnostic microbiology and infectious disease.

Use of the E test to predict high-level resistance to aminoglycosides among enterococci

R. Jones, M. L. Sánchez, M. Barrett, 1992, Journal of Clinical Microbiology.

In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

P. Murray, R. Jones, J. Washington, 1993, The Journal of antimicrobial chemotherapy.

Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef

R. Jones, D. Biedenbach, 1994, Journal of clinical microbiology.

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.

R. Jones, H. Cantrell, R. Lankford, 1994, Diagnostic microbiology and infectious disease.

Dilemmas of the Beta-Lactam Explosion

R. Jones, P. Fuchs, 1981, Infection Control.

Antimicrobial activity of imipenem and SCH34343 against Legionella species.

R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Reliability of high-content disks and modified broth dilution tests for detecting staphylococcal resistance to the penicillinase-resistant penicillins

R. Jones, A. Barry, 1987, Journal of Clinical Microbiology.

Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing m

R. Jones, M. Erwin, S. Worth, 1996, Diagnostic microbiology and infectious disease.

In vitro evaluation of E-4695, a new fluoro-naphthyridine

R. Jones, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria.

R. Jones, K. Aldridge, A. Bourgault, 1990, Reviews of infectious diseases.

The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections.

R. Jones, 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.

A. Watters, R. Jones, T. Fritsche, 2008, Journal of chemotherapy.

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

M. Castanheira, S. Lockhart, M. Pfaller, 2012, Journal of Clinical Microbiology.

Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellulare in blood culture fluids of AIDS patients

M. Cormican, R. Jones, 1995, Journal of clinical microbiology.

Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.

M. Cormican, R. Jones, M. Erwin, 1997, Diagnostic microbiology and infectious disease.

Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of CandidaSpecies

A. Bolmström, M. Pfaller, R. Jones, 2001, Journal of Clinical Microbiology.

Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates ofCandida Species

A. Bolmström, M. Pfaller, R. Jones, 2001, Journal of Clinical Microbiology.

Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testingHaemophilus influenzae on Haemophilus Test Medium

J. Hindler, G. Doern, R. Jones, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

Preliminary interpretive criteria for the Haemophilus test medium method using 30 µg cefepime disks

R. Jones, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

False resistance results using 5 µg cefixime disks to testHaemophilus influenzae

R. Jones, M. Erwin, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

207. Studies in the sterol group. Part XXIV. The constitution of calciferol

R. Jones, K. Samant, I. Heilbron, 1936 .

Special topics in antimicrobial susceptibility testing: test accuracy against methicillin-resistant Staphylococcus aureus, pneumococci, and the sensitivity of beta-lactamase methods.

R. Jones, D. Edson, 1984, American journal of clinical pathology.

Contemporary quality control practices for antimicrobial susceptibility tests: a report from the microbiology portion of the College of American Pathologists (CAP) surveys program.

R. Jones, D. Edson, B. Gilmore, 1983, American journal of clinical pathology.

Evaluations of antimicrobial susceptibility test proficiency by the College of American Pathologists Survey program. A clarification of quality control recommendations.

R. Jones, J. Marymont, D. Edson, 1982, American journal of clinical pathology.

The identification and antimicrobial susceptibility testing of Neisseria gonorrhoeae, 1980-1987. Results from the College of American Pathologists Microbiology Surveys Program.

R. Jones, D. Edson, 1988, Archives of pathology & laboratory medicine.

Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.

J. Verhoef, R. Jones, H. Sader, 1998, The Journal of antimicrobial chemotherapy.